Ad-REIC gene therapy: Promising results in a patient with metastatic CRPC following chemotherapy

Hiromi Kumon, Katsumi Sasaki, Yuichi Ariyoshi, Takuya Sadahira, Shin Ebara, Takao Hiraki, Susumu Kanazawa, Hiroyuki Yanai, Masami Watanabe, Yasutomo Nasu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induc-tion of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks’ interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalClinical Medicine Insights: Oncology
Volume9
DOIs
Publication statusPublished - Mar 23 2015

Fingerprint

Castration
Genetic Therapy
Prostatic Neoplasms
Drug Therapy
Injections
Cancer Vaccines
Prostate-Specific Antigen
Adenoviridae
Immunity
Lymph Nodes
Apoptosis
Neoplasm Metastasis
Genes
Neoplasms
Therapeutics

Keywords

  • Cancer gene therapy
  • Cancer vaccine
  • Metastatic castrate-resistant prostate cancer
  • REIC/Dkk-3 gene

ASJC Scopus subject areas

  • Oncology

Cite this

@article{7530f322e85145dcba645c635b07510b,
title = "Ad-REIC gene therapy: Promising results in a patient with metastatic CRPC following chemotherapy",
abstract = "A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induc-tion of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks’ interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.",
keywords = "Cancer gene therapy, Cancer vaccine, Metastatic castrate-resistant prostate cancer, REIC/Dkk-3 gene",
author = "Hiromi Kumon and Katsumi Sasaki and Yuichi Ariyoshi and Takuya Sadahira and Shin Ebara and Takao Hiraki and Susumu Kanazawa and Hiroyuki Yanai and Masami Watanabe and Yasutomo Nasu",
year = "2015",
month = "3",
day = "23",
doi = "10.4137/CMO.S23252",
language = "English",
volume = "9",
pages = "31--38",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Ad-REIC gene therapy

T2 - Promising results in a patient with metastatic CRPC following chemotherapy

AU - Kumon, Hiromi

AU - Sasaki, Katsumi

AU - Ariyoshi, Yuichi

AU - Sadahira, Takuya

AU - Ebara, Shin

AU - Hiraki, Takao

AU - Kanazawa, Susumu

AU - Yanai, Hiroyuki

AU - Watanabe, Masami

AU - Nasu, Yasutomo

PY - 2015/3/23

Y1 - 2015/3/23

N2 - A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induc-tion of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks’ interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.

AB - A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induc-tion of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in December 2012, the patient presented with rapid progression of lymph node (LN) metastases. Two scheduled Ad-REIC injections and 10 additional Ad-REIC injections into metastatic pelvic and para-aortic LNs under CT guidance, with an average four weeks’ interval, exhibited the potent direct and indirect effects of Ad-REIC as a therapeutic cancer vaccine. During the next 12 months, three additional injections into para-aortic LNs showing regrowth achieved adequate control of all metastatic LNs with prostate-specific antigen (PSA) decline, without any particular adverse events.

KW - Cancer gene therapy

KW - Cancer vaccine

KW - Metastatic castrate-resistant prostate cancer

KW - REIC/Dkk-3 gene

UR - http://www.scopus.com/inward/record.url?scp=84925664575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925664575&partnerID=8YFLogxK

U2 - 10.4137/CMO.S23252

DO - 10.4137/CMO.S23252

M3 - Article

AN - SCOPUS:84925664575

VL - 9

SP - 31

EP - 38

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -